+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CTI BioPharma Corp (CTIC) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 49 Pages
  • June 2023
  • GlobalData
  • ID: 1315527
CTI BioPharma Corp (CTIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company that acquires, develops, and commercializes novel therapies for a range of blood-related cancers. Its lead product, Pacritinib is intended for the treatment of patients with myeloproliferative diseases. Its product pipeline includes PACIFICA for the treatment of myelofibrosis patients with severe thrombocytopenia; PAC203 for the patients with ruxolitinib therapy failure; PRE-VENT for COVID-19; PERSIST 1 for all platelets count and PERSIST 2 for platelets counts less than thousand. The company’s commercialized product, Vonjo is targeted for the treatment of adult patients with myelofibrosis patients with severe thrombocytopenia. The company relies on third parties for manufacturing and marketing its products. CTI BioPharma is headquartered in Seattle, Washington, the US.

CTI BioPharma Corp Key Recent Developments

May 30, 2023: CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
Mar 06, 2023: CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 23, 2023: CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023
Sep 21, 2022: CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology Tenth Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • CTI BioPharma Corp - Key Facts
  • CTI BioPharma Corp - Key Employees
  • CTI BioPharma Corp - Key Employee Biographies
  • CTI BioPharma Corp - Major Products and Services
  • CTI BioPharma Corp - History
  • CTI BioPharma Corp - Company Statement
  • CTI BioPharma Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • CTI BioPharma Corp - Business Description
  • CTI BioPharma Corp - Corporate Strategy
  • CTI BioPharma Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • CTI BioPharma Corp - Strengths
  • CTI BioPharma Corp - Weaknesses
  • CTI BioPharma Corp - Opportunities
  • CTI BioPharma Corp - Threats
  • CTI BioPharma Corp - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • CTI BioPharma Corp, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 30, 2023: CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
  • Mar 06, 2023: CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results
  • Feb 23, 2023: CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023
  • Sep 21, 2022: CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology Tenth Annual Meeting
  • Aug 08, 2022: CTI BioPharma Reports Second Quarter 2022 Financial Results
  • Aug 01, 2022: CTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022
  • May 12, 2022: CTI BioPharma Reports First Quarter 2022 Financial Results
  • May 10, 2022: CTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
  • Mar 31, 2022: CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • CTI BioPharma Corp, Key Facts
  • CTI BioPharma Corp, Key Employees
  • CTI BioPharma Corp, Key Employee Biographies
  • CTI BioPharma Corp, Major Products and Services
  • CTI BioPharma Corp, History
  • CTI BioPharma Corp, Subsidiaries
  • CTI BioPharma Corp, Key Competitors
  • CTI BioPharma Corp, Ratios based on current share price
  • CTI BioPharma Corp, Annual Ratios
  • CTI BioPharma Corp, Interim Ratios
  • CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • CTI BioPharma Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • CTI BioPharma Corp, Performance Chart (2018 - 2022)
  • CTI BioPharma Corp, Ratio Charts
  • CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Clovis Oncology Inc
  • Bristol-Myers Squibb Co
  • Geron Corp
  • Novartis AG
  • Johnson & Johnson
  • Incyte Corp
  • Clovis Oncology Inc
  • Novartis AG
  • Incyte Corp
  • Geron Corp
  • Bristol-Myers Squibb Co
  • Johnson & Johnson